-
-
-
-
-
-
-
FDA grants orphan drug designation to Inhibikase's IKT-001 for PAH
-
-
-
-
-
-
-
Dexcom selected as first participant in FDA's TEMPO pilot
-
-
-
-
-
-
-
Forge Resources wraps Phase 1 drilling at Yukon's Alotta project
-
-
-
-
-
-
-
Radiopharm reports partial response in RAD204 cancer drug trial
-
-
-
-
-
-
-
Natera's Signatera outperforms AMERK in skin cancer recurrence study
-
-
-
-
-
-
-
Celldex's barzolvolimab fails Phase 2 trial in prurigo nodularis
-
-
-
-
-
-
-
Rein Therapeutics expands Phase 2 IPF trial to all five countries
-
76,438 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

